Enallylpropymal

Enallylpropymal (Narconumal) is a barbiturate derivative developed by Hoffman la Roche in the 1930s.[1] It has sedative and hypnotic effects and is considered to have a moderate abuse potential.[2]

Enallylpropymal
Clinical data
Other namesEnallylpropymal
ATC code
  • none
Identifiers
  • (RS)-1-Methyl-5-allyl-5-isopropyl-1,3-diazinane-2,4,6-trione
CAS Number
PubChem CID
ChemSpider
UNII
ECHA InfoCard100.015.876
Chemical and physical data
FormulaC11H16N2O3
Molar mass224.260 g·mol−1
3D model (JSmol)
ChiralityRacemic mixture
  • O=C1NC(=O)N(C)C(=O)C1(C(C)C)CC=C
  • InChI=1S/C11H16N2O3/c1-5-6-11(7(2)3)8(14)12-10(16)13(4)9(11)15/h5,7H,1,6H2,2-4H3,(H,12,14,16)
  • Key:AXJXURWWUFZZKN-UHFFFAOYSA-N
  (verify)

References
  1. US 2072829, Schnider O, "N-Methyl-5,5-allylisopropylbarbituric acid", issued 2 March 1937, assigned to Hoffmann-La Roche Inc.
  2. Eddy NB, Halbach H, Isbell H, Seevers MH (1965). "Drug dependence: its significance and characteristics". Bulletin of the World Health Organization. 32 (5): 721–33. PMC 2555251. PMID 5294186.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.